As antimalarial drug resistance grows more common, NIAID is funding research into drugs which may overcome the parasites' newabilities.

Monday, September 10, 2018 Early-Stage Clinical Trial of Antimalarial Drug Begins Malaria is one of the world's most serious mosquito-borne diseases; however, some strains of the malaria parasite are gaining resistance to common antimalarial drugs. In an early-stage clinical trial funded by NIAID, researchers are testing an experimental antimalarial drug which could overcome one form of the parasite's drug resistance.  National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID). This email was sent to rssproject471@gmail.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107

Tweet

Postingan terkait:

— Monday, September 10, 2018 — Add Comment